HURA
NASDAQ
$2.18
TuHURA Biosciences Inc (HURA)
TuHURA Biosciences Inc is an innovative biotechnology company at the forefront of developing cutting-edge immunotherapy solutions designed to transform the treatment landscape for cancer and autoimmune diseases. Leveraging a strong research pipeline, the company is focused on harnessing the full capabilities of the human immune system to improve patient outcomes and address unmet medical needs. With strategic partnerships and a commitment to pioneering technologies, TuHURA is well-positioned for long-term growth and value creation in the dynamic biopharmaceutical industry, aiming to become a key influencer in the future of healthcare.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $8.04 (+268.81%)
Market Cap
$151M
Free Cash Flow Yield
-18.10%
Price Chart
Valuation
Market Cap$151M
P/B6.56
Profitability
EBITDA-$30M
EPS-$0.56
Financial Health
Free Cash Flow Yield-18.10%
Growth & Risk
FCF 5Y CAGR+15.21%
Sharpe Ratio0.34